Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

March 04, 2023

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

News Conference News ACC 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

April 03, 2022

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

November 18, 2019

Visit-to-Visit BP Variability Linked to Coronary Plaque Progression, Adverse Outcomes

News Daily News

Visit-to-Visit BP Variability Linked to Coronary Plaque Progression, Adverse Outcomes

April 11, 2019

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

News Daily News

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

Michael O'Riordan

October 17, 2018

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

News Conference News TCT 2018

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

Yael L. Maxwell

September 24, 2018

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

People Living in Amazon Rainforest Provide Clues to Coronary Protection

News Conference News ACC 2017

People Living in Amazon Rainforest Provide Clues to Coronary Protection

March 17, 2017

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

News Daily News

Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT

Michael O'Riordan

September 29, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study

Michael O'Riordan

September 22, 2016

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Daily News

Review Touts Benefits of Statins, Seeks to Dispel Safety Concerns

September 12, 2016

News Daily News

粥样硬化性心血管疾病计算器是否会高估患者的风险？争论还在继续

Yael L. Maxwell

May 04, 2016

News Daily News

El Debate Sigue Abierto: ¿Sobrevalora la Calculadora de la Enfermedad Cardiovascular Aterosclerótica el Riesgo de los Pacientes?

Yael L. Maxwell

May 04, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.